Gastro Esophageal Junction Neuroendocrine Tumor Market

Market Overview:

The 7 major gastro esophageal junction neuroendocrine tumor markets reached a value of US$ 1,059.0 Million in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 1,965.3 Million by 2034, exhibiting a growth rate (CAGR) of 5.78% during 2024-2034.

The gastro esophageal junction neuroendocrine tumor market has been comprehensively analyzed in IMARC's new report titled "Gastro Esophageal Junction Neuroendocrine Tumor Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Gastro esophageal junction neuroendocrine tumor (GEJ-NET) is a rare type of cancer that originates from neuroendocrine cells in the area where the esophagus meets the stomach. These cells produce hormones that control various bodily functions. GEJ-NETs can exhibit a range of symptoms, often varying based on the tumor's size and extent of spread. Common indications include heartburn, difficulty swallowing, chest pain, unexplained weight loss, gastrointestinal bleeding, etc. However, due to their indolent nature, GEJ-NETs can remain asymptomatic in their early stages, making early diagnosis challenging. The diagnosis of the illness typically involves a combination of imaging techniques, such as computed tomography scans and magnetic resonance imaging, to visualize the tumor and determine its size and extent of spread. Tissue samples obtained through biopsy are also crucial for confirming the neuroendocrine nature of the tumor and assessing its aggressiveness. Additionally, blood tests are recommended to measure levels of specific hormones and biomarkers associated with the condition.

The increasing cases of genetic abnormalities, leading to changes in the structure or number of chromosomes within cells, are primarily driving the gastro esophageal junction neuroendocrine tumor market. In addition to this, the inflating utilization of peptide receptor radionuclide therapy (PRRT) that targets cancerous cells with precision and minimizes collateral damage to healthy tissues is also creating a positive outlook for the market. Moreover, the widespread adoption of efficacious treatments, such as somatostatin analogs, targeted therapies, and cytotoxic chemotherapy, which help to manage the tumor size and decelerate its progression, is further bolstering the market growth. Apart from this, the rising usage of nutrition therapy and dietary modifications, since they play an integral role in optimizing the patient's health and potentially attenuating symptoms, is acting as another significant growth-inducing factor. Additionally, the emerging demand for advanced endoscopic procedures, aiming at localized tumor removal and ensuring minimal invasiveness is also augmenting the market growth. Furthermore, the escalating popularity of radiological interventions to treat the disease on account of their numerous advantages, like shorter hospital stays, quicker recovery times, and reduced overall patient discomfort, is expected to drive the gastro esophageal junction neuroendocrine tumor market during the forecast period.

IMARC Group's new report provides an exhaustive analysis of the gastro esophageal junction neuroendocrine tumor market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for gastro esophageal junction neuroendocrine tumor and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the gastro esophageal junction neuroendocrine tumor market in any manner.

Time Period of the Study

• Base Year: 2023
• Historical Period: 2018-2023
• Market Forecast: 2024-2034

   

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan
   

Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the gastro esophageal junction neuroendocrine tumor market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the gastro esophageal junction neuroendocrine tumor market
• Reimbursement scenario in the market
• In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current gastro esophageal junction neuroendocrine tumor marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance

Key Questions Answered in this Report:

Market Insights

• How has the gastro esophageal junction neuroendocrine tumor market performed so far and how will it perform in the coming years?
• What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
• What was the country-wise size of the gastro esophageal junction neuroendocrine tumor market across the seven major markets in 2023 and what will it look like in 2034?
• What is the growth rate of the gastro esophageal junction neuroendocrine tumor market across the seven major markets and what will be the expected growth over the next ten years?
• What are the key unmet needs in the market?
   

Epidemiology Insights

• What is the number of prevalent cases (2018-2034) of gastro esophageal junction neuroendocrine tumor across the seven major markets?
• What is the number of prevalent cases (2018-2034) of gastro esophageal junction neuroendocrine tumor by age across the seven major markets?
• What is the number of prevalent cases (2018-2034) of gastro esophageal junction neuroendocrine tumor by gender across the seven major markets?
• How many patients are diagnosed (2018-2034) with gastro esophageal junction neuroendocrine tumor across the seven major markets?
• What is the size of the gastro esophageal junction neuroendocrine tumor patient pool (2018-2023) across the seven major markets?
• What would be the forecasted patient pool (2024-2034) across the seven major markets?
• What are the key factors driving the epidemiological trend of gastro esophageal junction neuroendocrine tumor?
• What will be the growth rate of patients across the seven major markets?
   

Gastro Esophageal Junction Neuroendocrine Tumor: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

• What are the current marketed drugs and what are their market performance?
• What are the key pipeline drugs and how are they expected to perform in the coming years?
• How safe are the current marketed drugs and what are their efficacies?
• How safe are the late-stage pipeline drugs and what are their efficacies?
• What are the current treatment guidelines for gastro esophageal junction neuroendocrine tumor drugs across the seven major markets?
• Who are the key companies in the market and what are their market shares?
• What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the gastro esophageal junction neuroendocrine tumor market?
• What are the key regulatory events related to the gastro esophageal junction neuroendocrine tumor market?
• What is the structure of clinical trial landscape by status related to the gastro esophageal junction neuroendocrine tumor market?
• What is the structure of clinical trial landscape by phase related to the gastro esophageal junction neuroendocrine tumor market?
• What is the structure of clinical trial landscape by route of administration related to the gastro esophageal junction neuroendocrine tumor market?